Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Projected EPS At $1.32 For Next Quarter


Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has a mean price target of $140.33 by market experts. Market leading group First Call has reached this recommendation by considering recommendations of top analysts in the industry. These experts have specified earnings of $1.32 a share for the very next quarter and $3.45 for this year.

Technical View

The technical study of Ligand Pharmaceuticals Incorpor demonstrates that the 50-day moving average of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock is $115.53, and is trading $0.01 points away or +0.01% from 50-day moving average of $115.53. It is trading $-0.40 or -0.35% away 200-day moving average of $115.94.

The 52-week high of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was $139.79 while $79.66 is the low mark in the same period. It state Ligand Pharmaceuticals Incorpor share price has to surge more than $-24.25 to hit 52-week high or drop +45.04% to make a 52-week mark. MA here hints at moving average.

Taking the valuation part to reach the estimation of Ligand Pharmaceuticals Incorpor, investors apply price-to-earnings ratio, which is shortened as P/E ratio. It weighs equity price by the relative expense of the equity. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ratio came in at 10.89, after dividing current equity price by yearly earnings. Ligand Pharmaceuticals Incorpor stock recorded a close of $115.54 in last trading session, registering a market cap of $2.41B.

The price-earnings ratio can be seen as a means of regulating the value of per dollar of earnings through the stock market. In concept, by taking the average of P/E over a period of numerous years, one could frame something of a uniform P/E ratio, which can then be understood as a benchmark and utilized to indicate whether or not a share is worth buying.

Investors estimate the Price-to-Earnings-Growth ratio to catch up with a clear view on the firm valuation. For stocks with higher PEG ratio, they are considered as sell option. The undervalued equity displays PEG ratio of 0 or 1. On contrary, the fairly valued equity has ratio of 1 and 2. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PEG ratio is at 0.73.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 10 times, 1 visits today)